MoonLake Immunotherapeutics Investors Urged to Take Action Now

Important Notice for MoonLake Immunotherapeutics Shareholders

In light of recent developments, all shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) are strongly advised to be aware of a significant securities fraud class action lawsuit. This legal action has been initiated against the company, and it involves allegations of misrepresentations related to the company's leading drug candidate, sonelokimab (SLK).

What Should Investors Know?

MoonLake Immunotherapeutics, commonly referred to as MoonLake, has become a focal point of legal scrutiny due to claims that the company, along with some of its senior executives, made misleading statements about the efficacy of its drug in comparison to other monoclonal antibody treatments.

Details of the Lawsuit

The lawsuit, filed in the Southern District of New York, targets those who acquired shares of MoonLake within a specified time frame, from March 10, 2024, through September 29, 2025. The allegations highlight potential violations under the Securities Exchange Act of 1934, emphasizing the impact these misleading claims could have on investors' financial health.

Eligibility for Participation

Investors who purchased shares during this time period and believe they may have suffered losses are encouraged to review their options for joining this legal action. Importantly, involvement in this class action isn’t mandatory for recovering potential damages.

Deadline for Filing Claims

Individuals wishing to act as lead plaintiffs must file their paperwork by December 15, 2025. Being a lead plaintiff means taking on the responsibility of representing the entire class, but it isn’t a prerequisite for receiving any financial recovery.

Your Rights as a Shareholder

All legal representation related to this case will be handled on a contingency fee basis, ensuring that shareholders incur no upfront costs. This means that you won’t pay any fees unless a successful outcome is achieved in court.

Call to Action for Investors

If you believe that your investment in MoonLake Immunotherapeutics was affected by the alleged misrepresentations, it’s crucial to stay informed and proactive about your rights. Numerous resources are available to you for gaining a better understanding of the ongoing situation and for receiving assistance with any claims you may wish to file.

The Role of Bernstein Liebhard LLP

Bernstein Liebhard LLP, a reputable law firm that specializes in investor rights, is leading the charge in representing shareholders affected by this situation. With a strong track record of securing over $3.5 billion for its clients, this firm has extensive experience in navigating securities class actions. They have represented individual investors as well as larger institutional funds, reflecting their commitment to safeguarding the interests of all their clients.

Contact Information

For any individuals who wish to learn more or discuss their potential involvement in this class action lawsuit, please reach out to Investor Relations Manager Peter Allocco at (212) 951-2030 or via email at pallocco@bernlieb.com. You may also visit the official website for additional information and resources.

Frequently Asked Questions

What is the class action lawsuit against MoonLake Immunotherapeutics about?

The lawsuit alleges that MoonLake and certain executives made false statements regarding the effectiveness of their drug candidate, sonelokimab.

Who is eligible to join this class action?

Investors who purchased shares of MoonLake between March 10, 2024, and September 29, 2025, are eligible to join.

What is the deadline for filing claims?

The deadline to file as a lead plaintiff is December 15, 2025.

Will I have to pay fees to join the lawsuit?

No, representation is on a contingency fee basis, meaning you only pay if the case is successful.

How can I contact someone for more information?

You can contact Peter Allocco at (212) 951-2030 or email him at pallocco@bernlieb.com for more details.

About The Author

Riley Hayes here, a financial writer and specialist committed to assisting individuals in navigating the intricate world of finance. My love is using my blog and articles to simplify complex financial ideas into understandable, doable guidance. Having worked in finance for many years, I try to give my readers the information and resources they need to make wise financial choices.

Writing for several financial blogs has let me connect with a wide range of readers, from novice investors seeking new ideas to seasoned investors. My mission is to make money interesting and approachable so you may take charge of your financial future. I appreciate you traveling with me toward success and financial literacy.

Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.